Morgan Stanley maintains its Underweight rating and $35 target on Athenahealth ATHN ahead of the company's investor day, which will set CY12 expectations.
Morgan Stanley comments, “We expect incremental visibility to ATHN's CY12 outlook at its Investor Day (December 15). Revenue estimates appear attainable, but EPS may be at risk due to the increased operating expenses associated with marketing to small physician offices.”
ATHN closed at $59.93 per share on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in